How Mounjaro helps with weight loss: the real mechanism

The biggest misconception: Mounjaro is not just an appetite suppressant

A common assumption is that tirzepatide works in a single, straightforward way, it makes you feel less hungry, so you eat less. That framing is not wrong, but it is incomplete in a way that matters. The mechanism is more layered, and understanding it helps explain both why results can be significant and why side effects follow a particular pattern.

Mounjaro activates two receptors: the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. GLP-1 agonism is something it shares with semaglutide (Wegovy). The GIP pathway is what makes tirzepatide distinct, it is the only dual-agonist weight-loss medicine licensed in the UK. The NHS medicines page for tirzepatide describes the combined action as affecting appetite signalling and blood-sugar regulation together.

GLP-1 receptor activation slows gastric emptying, food moves from the stomach into the intestine more slowly, which prolongs the physical sensation of being full after eating. It also acts on areas of the brain involved in appetite regulation, reducing cravings and the drive to eat beyond what the body needs. The GIP receptor appears to amplify these effects and may also influence how the body handles energy storage, though research in this area continues. For a fuller look at how Mounjaro's mechanism drives weight loss, that question is covered in detail separately.

The combined result is a significant and sustained reduction in calorie intake, not through willpower, but through biology. Weight in this context is a physiological condition, not a moral one.

What the clinical evidence actually shows

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity (without type 2 diabetes) to tirzepatide or placebo over 72 weeks. At the 15 mg dose, average body-weight reduction was around 20–21%. Lower doses produced meaningful reductions too, the graduated titration schedule means almost everyone sees some benefit before reaching the maximum dose. NICE's appraisal of tirzepatide (TA1026) reviewed this evidence and recommended tirzepatide as a treatment option, noting the strength of the trial programme.

In a separate head-to-head trial (SURMOUNT-5, published in 2025), tirzepatide produced greater average weight reduction than semaglutide 2.4 mg over 72 weeks in adults with obesity. That comparison matters because semaglutide had itself been shown to achieve around 15% average weight loss in the STEP 1 trial. Both are considerable results; which is more appropriate for a given person is a clinical question, not a marketing one. If you want a side-by-side look at the two medicines, the evidence behind Mounjaro's weight-loss results covers the numbers in more depth.

One practical note: the starting dose of 2.5 mg is a tolerability measure. Its job is to settle your digestive system into the medicine's mechanism before the dose increases, it is not the dose at which most people see significant weight reduction. The prescriber titrates upward, typically in four-week steps, to the highest dose that works well for you.

Why the side-effect profile makes sense once you know the mechanism

Because tirzepatide slows gastric emptying and acts on gut receptors, the most common side effects are gastrointestinal: nausea, loose stools or constipation, indigestion, and occasionally vomiting or burping. These tend to be most noticeable after starting the medicine or following a dose increase, and they usually settle over a few days to two weeks as the body adjusts. The NHS medicines page for tirzepatide sets out the full side-effect profile clearly.

More serious effects are less common but should not be ignored. Severe, persistent stomach pain that spreads to the back (with or without vomiting) warrants urgent medical attention because it can be a sign of pancreatitis. The MHRA highlighted acute pancreatitis as a known, infrequent but potentially serious risk in a Drug Safety Update in January 2026. Any suspected side effects can be reported through the Yellow Card scheme at yellowcard.mhra.gov.uk.

Indigestion and reflux are among the questions our prescribers field most often, if you take an antacid like Gaviscon alongside tirzepatide, there are timing considerations worth being aware of; the Gaviscon and Mounjaro interaction page covers what is currently known. As always, your prescriber or Patient Information Leaflet is the first place to check for your specific situation.

Who the medicine is licensed for, and what assessment involves

UK licensing covers adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes, prediabetes or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. BMI alone does not determine suitability; a prescriber reviews the full picture.

Tirzepatide is not recommended during pregnancy, breastfeeding, or for people who are actively trying to conceive. It is not licensed for under-18s. Certain conditions (including a history of medullary thyroid carcinoma or pancreatitis) require careful discussion with a clinician before any decision is made.

If you are exploring whether Mounjaro could be right for you, the tirzepatide overview covers eligibility in more detail, and the weight-loss treatment overview sets out how the different licensed options compare. If you have questions about how Mounjaro helps you lose weight, including what to expect at each stage of treatment, that is covered separately in its own guide. Ordering by a Monday means treatment can reach you before the week really starts, something worth knowing if timing matters to your routine. For a regulated private route that includes a same-day clinical review by a GPhC-registered prescriber and free next-working-day delivery, you can speak to our prescribers through a free consultation, and if you want to understand more about whether tirzepatide helps with weight loss and what the evidence says about real-world outcomes, that page brings together the key findings in one place.